AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$XGN

Exagen Inc. Reports Third Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% November 10, 2026 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a precisio

Original reporting
SEC EDGAR 8-K
Published Nov 10, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$XGN
Neutral
medium confidence
Mentioned
$XGN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$XGNNeutralLow
01

Why it matters

The Q3 release confirms continued revenue growth and cash position, but the reaffirmed guidance suggests no major upside catalyst.

02

Market read

The filing is a primary earnings disclosure for a micro‑cap; relevance is limited to investors tracking niche biotech stocks.

03

Timing

today

Relevance 7/10Novelty 7/10Timing: today

Background

Exagen is a precision‑medicine diagnostics company focused on autoimmune disease testing.

Company-level read

Ticker impact

$XGNNeutralMedium confidence
Context

Exagen Inc. filed an 8‑K reporting Q3 2026 results with revenue up 7% to $18.4M and reaffirmed full‑year guidance of $72‑75M.

Expected impact

likely limited pressure as the market prices in steady guidance and modest top‑line growth

Evidence & confidence

The numbers are new but the scale is small for a micro‑cap; reaffirmed guidance does not change expectations, so price reaction should be muted.

Market effects

Sector

Provides a modest data point for the niche autoimmune diagnostics sector.

Regional

Limited impact confined to the biotech niche; no broader regional effect.

Global

Minimal global relevance beyond sector analysts.

Key entities

  • Executive
    John Aballi

    President and CEO of Exagen, quoted in the release.

Read at source← All news

Related articles

$XGNMedAI 8/10

Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance

Exagen (NASDAQ:XGN) reported record Q2 2026 revenue of $19.9 million, up 16% year over year, driven by an 11% rise in AVISE CTD testing volume and a 4% higher trailing twelve-month average selling price to $446 per test. Adjusted EBITDA loss narrowed to $0.1 million. Exagen raised full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million.

yahoo.com
$XGNMedAI 8/10

Exagen Inc. Q2 2026 Earnings Call Summary

Exagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.

yahoo.com
$XGNMed

Exagen Inc. Reports Second Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million August 4,

SEC EDGAR 8-K
$LCIDHighAI 8/10

Lucid Jumps 8% on $1.75 Billion Liquidity Boost Despite Q3 Miss; Rivian Dips, Tesla Little Changed

Lucid Group (LCID) stock rose 8% to $3.90 after announcing a $1.75 billion loan expansion with Saudi Arabia's PIF, boosting liquidity to $3.75 billion. Despite missing Q3 revenue and earnings estimates, investors focused on improved cash burn and extended runway. CEO Silvio Napoli highlighted progress in transformation and cost savings. Rivian (RIVN) and Tesla (TSLA) stocks were little changed.

247wallst.com